id,indicator_code,spatial_dim_type,iso_code,time_dim_type,region_code,region,dim1type,dim1,year,dim2type,dim2,dim3type,dim3,data_source_dim_type,data_source_dim,value,numeric_value,low,high,comments,date,time_dimension_value,time_dimension_begin,time_dimension_end,country,indicator_name,language,title
1430,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,92.3,92.34899,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6097,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,61.9,61.85567,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
16592,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
16954,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,34.8,34.84487,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
22655,TB_rdst_num_prct,COUNTRY,COM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Comoros,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
24761,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,34.3,34.28571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
27619,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,61.9,61.85144,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
39204,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
62021,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,96.7,96.65328,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
67567,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,364.7,364.70588,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
68696,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,74.8,74.7606,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
74678,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,93.3,93.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
76128,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.3,96.33884,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
78509,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,73.9,73.91304,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
86574,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,30.6,30.60157,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
100963,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,89.2,89.22951,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
102021,TB_rdst_num_prct,COUNTRY,PSE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,"occupied Palestinian territory, including east Jerusalem",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
110362,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,90.3,90.25157,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
113949,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,7.8,7.79221,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
119096,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,68.4,68.40391,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
120277,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,24.4,24.39863,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
128811,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,90.3,90.29126,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
132630,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,86.9,86.93333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
138091,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,60.7,60.72545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
139405,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,95.5,95.49919,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
142833,TB_rdst_num_prct,COUNTRY,ECU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,81.8,81.75923,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ecuador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
152489,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,63.2,63.15789,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
161247,TB_rdst_num_prct,COUNTRY,ABW,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Aruba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
167192,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.6,92.64813,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
171868,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,77.8,77.77778,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
185702,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,73.0,73.03665,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
192425,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,24.1,24.06904,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
201050,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,85.1,85.0718,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
209880,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,66.8,66.80672,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
215659,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,92.9,92.85714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
216862,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,37.7,37.70492,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
220207,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
226863,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,61.3,61.27168,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
227438,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
241124,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,1.5,1.45175,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
243873,TB_rdst_num_prct,COUNTRY,ECU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,25.5,25.45164,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ecuador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
247995,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
259844,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
262361,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,1.6,1.61943,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
271759,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,85.0,85.01963,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
279987,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,151.4,151.37615,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
283472,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,97.1,97.11844,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
283514,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,91.2,91.22807,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
283865,TB_rdst_num_prct,COUNTRY,TCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Turks and Caicos Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
284570,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
287567,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,30.5,30.4878,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
287776,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,36.9,36.88312,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
293651,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,35.3,35.29412,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
294942,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,90.4,90.35088,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
304370,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,87.5,87.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
305783,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.1,97.09544,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
315705,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,93.9,93.88654,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
319982,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,93.2,93.20388,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
323979,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
328115,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,37.7,37.72152,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
332343,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
358959,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,97.7,97.72727,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
374506,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
379384,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,97.9,97.88732,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
386356,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,66.2,66.17647,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
393597,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,4.6,4.63851,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
396769,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.1,96.1039,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
396939,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
401612,TB_rdst_num_prct,COUNTRY,BWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,147.0,146.9697,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Botswana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
405211,TB_rdst_num_prct,COUNTRY,TON,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Tonga,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
411012,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,96.4,96.40288,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
430559,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,80.8,80.76923,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
433027,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,44.3,44.34514,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
436580,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,66.7,66.68803,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
452697,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,65.1,65.0684,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
453764,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,68.3,68.30289,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
457641,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,16.4,16.35938,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
460253,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
461751,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,88.6,88.56552,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
465806,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,92.0,92.01903,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
466197,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,57.9,57.85012,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
470817,TB_rdst_num_prct,COUNTRY,BRB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Barbados,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
471077,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
483617,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,4.3,4.33119,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
501709,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,65.4,65.38462,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
505820,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
511462,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,98.4,98.4252,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
513693,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.7,0.71866,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
516466,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,28.6,28.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
518134,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,97.5,97.47784,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
520609,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,96.7,96.72073,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
527636,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
531534,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,95.8,95.78947,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
533172,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
533947,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,75.6,75.57803,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
542204,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,39.3,39.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
543067,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,76.1,76.11114,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
559561,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,60.4,60.38522,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
560898,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,76.5,76.47059,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
565617,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
569936,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,87.6,87.55778,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
573643,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
578932,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,47.7,47.70642,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
590117,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,70.6,70.58824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
590448,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,140.6,140.625,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
592986,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,91.3,91.30435,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
597536,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,95.8,95.83333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
605823,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
617513,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
630064,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,72.3,72.26277,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
634373,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,85.7,85.66321,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
634966,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
637166,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,92.6,92.5776,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
651586,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
659125,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,85.3,85.26316,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
665484,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,46.7,46.71991,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
670372,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
676603,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,34.5,34.53139,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
683950,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,82.1,82.0977,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
709891,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,70.6,70.58824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
711019,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,86.9,86.88525,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
713173,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,80.3,80.33539,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
714289,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,79.1,79.11765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
715372,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,95.1,95.1417,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
728352,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,56.7,56.67937,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
729016,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,82.0,81.99777,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
752998,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
754827,TB_rdst_num_prct,COUNTRY,ATG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Antigua and Barbuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
761468,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,1.3,1.30187,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
771428,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,39.9,39.88571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
778364,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,26.3,26.3164,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
779895,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,84.4,84.387200000000007,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
781235,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
794499,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
794790,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,88.4,88.4311,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
803378,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,60.9,60.86957,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
814998,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
819929,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.8,96.76674,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
820665,TB_rdst_num_prct,COUNTRY,SXM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sint Maarten (Dutch part),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
821406,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
826948,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,12.3,12.32227,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
837814,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
839741,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,83.7,83.72093,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
845995,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,73.4,73.4375,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
846093,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,84.4,84.41558,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
854156,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,71.0,70.96774,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
855131,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,40.0,40,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
862225,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,96.6,96.57895,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
867310,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,93.8,93.75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
871025,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.5,92.49877,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
880567,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
889032,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,22.9,22.91001,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
903756,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,82.6,82.56545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
908074,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,17.0,17.04545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
909693,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,38.7,38.71583,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
916248,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
919943,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,98.8,98.78049,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
920725,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,13.8,13.81074,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
920808,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,53.5,53.46015,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
928486,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,41.0,40.98026,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
936662,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,16.5,16.47621,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
939526,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,86.1,86.08361,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
945351,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,45.1,45.14887,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
962848,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,59.9,59.90453,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
973765,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,6.6,6.56182,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
975032,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.0,96.96181,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
978806,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,16.3,16.31356,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
980227,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,40.0,40,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
995881,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,44.3,44.31735,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1007662,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,89.9,89.94975,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1017500,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,86.3,86.26198,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1020312,TB_rdst_num_prct,COUNTRY,LVA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,92.3,92.30769,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Latvia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1022261,TB_rdst_num_prct,COUNTRY,TKM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Turkmenistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1029082,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,87.8,87.78622,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1032613,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1032870,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,73.5,73.46939,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1033149,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,57.6,57.59162,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1038602,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1043113,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1046222,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1053481,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1055686,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1058428,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,30.8,30.79224,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1060285,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,70.5,70.47414,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1065699,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,57.8,57.81298,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1068969,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,8.8,8.7848,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1081320,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,34.9,34.85501,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1084258,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,63.7,63.69193,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1089055,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,76.5,76.47059,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1089231,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1098531,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1110374,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.4,96.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1112130,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,81.8,81.81818,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1119695,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,95.0,95.0188,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1119717,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1136043,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,88.6,88.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1136326,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,62.5,62.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1138453,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1142067,TB_rdst_num_prct,COUNTRY,CYM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cayman Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1149935,TB_rdst_num_prct,COUNTRY,KNA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Saint Kitts and Nevis,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1157485,TB_rdst_num_prct,COUNTRY,KHM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,73.0,73.00384,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cambodia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1160951,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1168047,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1171511,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1191261,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,1.3,1.31752,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1191588,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,96.2,96.15385,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1193843,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1198716,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,72.2,72.19512,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1199366,TB_rdst_num_prct,COUNTRY,PSE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"occupied Palestinian territory, including east Jerusalem",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1204785,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1206861,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1209068,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,57.4,57.41355,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1216813,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1219561,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,51.0,51.01708,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1224403,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,91.3,91.30435,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1231467,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,55.3,55.26964,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1234963,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,90.8,90.75805,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1238974,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,92.8,92.75862,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1240732,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,94.8,94.82609,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1244165,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,56.0,56.04604,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1257866,TB_rdst_num_prct,COUNTRY,BRB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Barbados,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1260434,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,46.5,46.53465,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1291519,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.4,92.38095,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1293314,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,99.2,99.15966,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1295034,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,89.7,89.73607,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1297542,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,10.5,10.48601,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1312779,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,96.7,96.66812,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1314756,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.0,83.96226,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1324051,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1328455,TB_rdst_num_prct,COUNTRY,ABW,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Aruba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1330745,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,33.3,33.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1335546,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1340124,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1344543,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,53.6,53.64519,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1346673,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,86.7,86.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1347028,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1349204,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1359669,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,99.3,99.32895,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1369967,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,97.7,97.71585,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1378515,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,36.8,36.80599,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1381727,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1388277,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1393427,TB_rdst_num_prct,COUNTRY,VCT,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1394973,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,14.9,14.92715,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1404520,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.1,86.121,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1407261,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,60.6,60.55662,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1408516,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1418721,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,68.9,68.89339,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1419715,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,62.3,62.31884,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1421774,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,78.7,78.65447,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1421851,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1429915,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,76.3,76.27423,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1431083,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,83.0,83.03571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1433275,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,95.3,95.34767,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1436357,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,79.9,79.9174,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1441325,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.6,0.55226,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1442161,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,62.6,62.61215,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1442523,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.2,0.17946,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1443774,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,29.8,29.79798,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1474104,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,57.1,57.14286,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1474112,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,92.9,92.88991,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1474997,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,94.0,93.99906,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1482725,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1483474,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,53.6,53.58689,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1484453,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,80.3,80.25201,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1488458,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,58.8,58.82353,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1489828,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,98.0,98.00676,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1496896,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,4.1,4.12621,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1502432,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,96.4,96.38554,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1512566,TB_rdst_num_prct,COUNTRY,NRU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nauru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1514602,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.2,0.16721,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1517358,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,150.0,150,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1521389,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,56.2,56.23722,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1527212,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,77.1,77.11443,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1541327,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,11.2,11.20278,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1549151,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,73.2,73.24415,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1552546,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,75.1,75.14373,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1556356,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,34.0,34.03805,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1568471,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,86.3,86.3354,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1579002,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1579423,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,20.8,20.83333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1583472,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1595199,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,65.7,65.65958,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1595942,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,29.0,28.97196,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1596977,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,89.1,89.13043,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1599866,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1603273,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1608181,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,47.2,47.22222,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1610808,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,67.3,67.25625,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1620018,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1621209,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,84.0,84.04255,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1621732,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,87.0,86.99552,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1631003,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.8,96.77419,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1636560,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,47.9,47.92658,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1638247,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1643027,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,72.0,71.97146,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1651862,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1653563,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,39.2,39.23077,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1656571,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,88.1,88.12392,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1671383,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,22.6,22.56809,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1680926,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,46.8,46.76388,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1691969,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,76.4,76.40449,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1694178,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1700983,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,51.5,51.50215,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1703581,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,99.8,99.79058,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1713480,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,98.4,98.36289,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1721513,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,65.7,65.69873,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1723924,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1739735,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1742646,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,86.8,86.84211,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1746831,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,27.5,27.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1747858,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,94.1,94.06132,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1759012,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,93.8,93.78109,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1785355,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,217.8,217.80063,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1794274,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,63.6,63.57616,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1795854,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,97.2,97.24618,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1797871,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,85.1,85.14046,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1798431,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,69.8,69.75069,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1810120,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,91.8,91.82814,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1817383,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,42.1,42.06681,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1818597,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,83.4,83.39305,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1823570,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1825841,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,8.1,8.14763,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1826368,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,42.7,42.70877,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1828369,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1841555,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1855048,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1859610,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,77.8,77.84106,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1866626,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,94.6,94.62264,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1869934,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,90.4,90.37356,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1871670,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,91.3,91.30435,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1872735,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,50.7,50.71447,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1874243,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,81.3,81.25862,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1877076,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,69.2,69.19897,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1882763,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,86.7,86.71913,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1882890,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,79.5,79.48718,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1885685,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,55.5,55.45244,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1892365,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,42.4,42.38329,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1901236,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,82.0,81.99052,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1901524,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,50.6,50.62469,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1902112,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.1,93.06643,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1907032,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,94.1,94.11765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1910415,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.4,91.44717,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1921949,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,37.5,37.48723,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1928654,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.9,87.93103,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1962263,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,88.2,88.18303,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1968751,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1969057,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,89.1,89.11157,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1976356,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.8,94.78261,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1978066,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,12.8,12.76596,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1979418,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,26.9,26.89655,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1990547,TB_rdst_num_prct,COUNTRY,ECU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,87.8,87.79528,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ecuador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1993515,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,97.8,97.81659,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2005374,TB_rdst_num_prct,COUNTRY,NRU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nauru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2007741,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,33.9,33.89206,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2008869,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,84.3,84.34241,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2011793,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,51.6,51.61194,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2023782,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,97.3,97.26101,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2035516,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,96.0,96,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2046430,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,95.4,95.40984,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2058022,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,57.6,57.5734,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2063069,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.6,92.55319,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2090294,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,45.1,45.09103,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2094306,TB_rdst_num_prct,COUNTRY,ISL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iceland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2106269,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,53.6,53.6,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2117373,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2124134,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2129676,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,79.8,79.81307,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2131214,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2135786,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2145923,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,80.8,80.84507,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2154427,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,29.5,29.51447,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2159439,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,10.0,9.96897,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2172345,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,80.0,80,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2183962,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,96.2,96.2406,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2187252,TB_rdst_num_prct,COUNTRY,MLT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,87.2,87.17949,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malta,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2191314,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,70.5,70.49373,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2199777,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,97.2,97.17514,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2209336,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,95.1,95.12485,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2211796,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,46.7,46.72131,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2212429,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,82.4,82.35294,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2212959,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2214606,TB_rdst_num_prct,COUNTRY,TKM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Turkmenistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2236243,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,58.7,58.72385,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2236608,TB_rdst_num_prct,COUNTRY,LUX,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Luxembourg,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2262877,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,84.4,84.375,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2268110,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2275242,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,26.3,26.34352,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2278334,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,65.4,65.41889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2281732,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,71.1,71.05263,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2285663,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2296556,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2298881,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,86.5,86.49886,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2300191,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2327414,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,95.9,95.91837,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2331564,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2343618,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2347062,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2347730,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,40.2,40.19608,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2359240,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.8,78.84615,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2379076,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2379785,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,82.6,82.64967,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2382834,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2402214,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,68.1,68.11041,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2404630,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,99.7,99.74849,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2413478,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2416733,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,90.2,90.1553,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2417334,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,58.6,58.62069,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2417455,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2419086,TB_rdst_num_prct,COUNTRY,TON,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tonga,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2423601,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2425187,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,29.2,29.15173,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2426475,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,43.8,43.83736,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2434952,TB_rdst_num_prct,COUNTRY,ATG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Antigua and Barbuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2439714,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2451601,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,85.6,85.59322,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2459911,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2479468,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,62.2,62.16216,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2481645,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,95.7,95.68966,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2484235,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,6.2,6.15349,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2493890,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,82.6,82.63889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2495287,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,70.0,70,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2497912,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.1,96.11187,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2511961,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2526587,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2530938,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,62.2,62.20281,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2533734,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2534836,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2534924,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,56.3,56.25,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2543548,TB_rdst_num_prct,COUNTRY,LBY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Libya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2545771,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,76.6,76.55914,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2546949,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,97.4,97.4359,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2549098,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,97.6,97.63049,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2551257,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2566244,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,33.8,33.8488,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2578431,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,56.6,56.55577,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2579665,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,94.0,93.96552,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2592193,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,92.3,92.30769,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2607077,TB_rdst_num_prct,COUNTRY,DMA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Dominica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2611615,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,26.3,26.31579,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2613666,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2622699,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,36.4,36.41381,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2624429,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,28.9,28.89423,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2625863,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,84.8,84.79087,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2627778,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,26.6,26.59933,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2628684,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,67.2,67.22689,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2636030,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,91.5,91.51786,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2636975,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,28.3,28.30161,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2641374,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2648312,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,75.0,75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2653958,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2655390,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.9,87.87879,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2663612,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2665112,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2665473,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,91.8,91.75339,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2668499,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,35.5,35.45918,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2673930,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,82.0,81.98593,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2705383,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,78.8,78.84615,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2706818,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,91.2,91.17389,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2716255,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,95.2,95.21912,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2728466,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,95.5,95.54455,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2734830,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,89.3,89.26469,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2736336,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,92.9,92.85714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2737184,TB_rdst_num_prct,COUNTRY,LUX,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Luxembourg,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2743489,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2749283,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,83.1,83.10502,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2751574,TB_rdst_num_prct,COUNTRY,CYM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cayman Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2756140,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,92.5,92.48252,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2756400,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,95.9,95.92476,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2757279,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2759000,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,58.0,57.97222,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2759150,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2759733,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2763505,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,56.5,56.48253,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2767241,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2767513,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,86.1,86.13861,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2769028,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,59.8,59.79381,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2790125,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2791438,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,80.1,80.13468,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2793832,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,77.8,77.77778,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2794984,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,73.4,73.35979,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2798082,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,23.9,23.92527,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2823195,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2828027,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,60.8,60.76389,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2829570,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,70.3,70.27027,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2844902,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.2,91.2,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2850650,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,117.9,117.8733,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2867966,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,93.3,93.32391,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2898283,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,83.5,83.47904,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2911899,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2916313,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,83.7,83.67347,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2918352,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,68.5,68.54305,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2926978,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,85.4,85.43918,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2941316,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2944681,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,6.5,6.53074,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2948430,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2950726,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,38.6,38.56685,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2951710,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,83.5,83.4571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2952695,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2958560,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,168.6,168.60707,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2961072,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,84.4,84.375,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2967131,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,93.3,93.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2972883,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2975978,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,86.4,86.35478,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2980760,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,65.5,65.45455,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2985407,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2991625,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,65.2,65.24725,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2994544,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2998273,TB_rdst_num_prct,COUNTRY,COK,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cook Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3002499,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.8,93.75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3011769,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3012101,TB_rdst_num_prct,COUNTRY,VCT,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3012833,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3016092,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,92.6,92.63804,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3021218,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,90.3,90.31427,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3021452,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,76.1,76.08696,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3045586,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,50.0,50,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3046250,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3051647,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,51.5,51.51515,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3057774,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,32.7,32.73255,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3057818,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,89.0,89.04236,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3057958,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3062293,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,15.8,15.83152,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3067746,TB_rdst_num_prct,COUNTRY,CUW,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Curaao,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3070198,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,51.3,51.25487,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3095920,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,39.6,39.55224,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3098705,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,78.7,78.69416,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3117031,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,23.3,23.3279,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3122715,TB_rdst_num_prct,COUNTRY,SXM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sint Maarten (Dutch part),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3122844,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,67.5,67.49933,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3127013,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3128679,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,72.7,72.72727,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3129532,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,92.9,92.93286,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3136618,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.5,0.54945,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3142628,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,74.8,74.82014,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3150488,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,41.4,41.38973,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3152316,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,84.4,84.39364,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3157890,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,97.3,97.31707,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3165600,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3175216,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,92.0,92,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3179727,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3179854,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3182743,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3183290,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3185769,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,69.8,69.79138,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3190303,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3192557,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3200286,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,79.3,79.31034,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3201293,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,47.1,47.05882,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3204045,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,4.4,4.36137,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3204761,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,26.2,26.17914,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3215424,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,29.0,29.03587,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3222652,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,89.0,88.95582,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3242285,TB_rdst_num_prct,COUNTRY,LBY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,78.6,78.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Libya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3245104,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,87.5,87.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3245327,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3246785,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,84.0,84.04255,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3248774,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,69.2,69.23077,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3253242,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3255771,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.9,97.87234,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3262073,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3266235,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.8,89.84314,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3268392,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3269503,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3270699,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,98.1,98.07692,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3273447,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,63.2,63.17829,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3282029,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,94.8,94.77477,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3313716,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,92.0,92,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3314584,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3320763,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,39.9,39.90826,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3332623,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,2.1,2.08333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3333692,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3354518,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,59.3,59.32203,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3355574,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,81.4,81.40351,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3398045,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,74.1,74.07407,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3404926,TB_rdst_num_prct,COUNTRY,TCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Turks and Caicos Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3406618,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,84.0,84.02367,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3408034,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,85.2,85.18519,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3415533,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,77.0,76.97063,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3417833,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,38.0,38,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3418484,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,26.8,26.76209,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3419697,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.6,96.55778,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3422515,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,10.9,10.86957,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3428971,TB_rdst_num_prct,COUNTRY,AND,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,50.0,50,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Andorra,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3433026,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,103.5,103.5468,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3433907,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3438336,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3453901,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,16.0,16,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3462191,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,80.2,80.18868,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3471954,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3479635,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,16.0,15.97589,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3488620,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.6,0.6381,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3494034,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,24.9,24.89001,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3504925,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3506504,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3519806,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.2,90.18961,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3520297,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,73.2,73.17105,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3525427,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3533417,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3536303,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3536311,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,80.5,80.48128,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3542759,TB_rdst_num_prct,COUNTRY,PSE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"occupied Palestinian territory, including east Jerusalem",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3543447,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,65.4,65.40935,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3564522,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3580801,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,82.1,82.05763,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3583063,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,60.3,60.2653,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3596747,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3597354,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,86.8,86.84211,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3600401,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,99.0,99.02439,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3606359,TB_rdst_num_prct,COUNTRY,NRU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nauru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3607121,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.9,78.91994,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3608026,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,62.9,62.88253,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3618318,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,24.9,24.90984,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3620132,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,94.8,94.81481,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3620377,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,64.7,64.74423,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3626907,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,65.9,65.875,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3627011,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,92.1,92.07921,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3627130,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,86.7,86.70213,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3627199,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,41.4,41.39851,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3640546,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,98.3,98.29932,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3642003,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,82.1,82.13058,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3643772,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,93.8,93.75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3645890,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,92.4,92.42192,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3650101,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,96.9,96.875,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3659613,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.5,0.45597,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3669362,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3683710,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,29.8,29.79749,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3687417,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3695293,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,60.0,60,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3699901,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3701925,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,56.6,56.59152,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3705471,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,29.2,29.21748,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3705751,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,55.8,55.81152,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3720563,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,10.1,10.05634,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3725686,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,49.8,49.8246,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3732003,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3736014,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3741029,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3750017,TB_rdst_num_prct,COUNTRY,LVA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Latvia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3762645,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,89.7,89.7238,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3775756,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,44.9,44.86983,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3797878,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3800395,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3800796,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3812629,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,22.3,22.34584,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3818672,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,90.0,90,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3820417,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3832830,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,82.1,82.06751,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3851532,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,1.2,1.23967,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3851927,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,75.0,75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3856205,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,79.0,79.03572,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3857261,TB_rdst_num_prct,COUNTRY,LCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Saint Lucia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3863437,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,73.6,73.6,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3877794,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,54.4,54.36464,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3878393,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,26.3,26.31579,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3878821,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,52.3,52.25904,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3885808,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,88.1,88.11295,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3894931,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.3,0.26252,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3897679,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,88.2,88.23529,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3902376,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,36.6,36.61582,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3902824,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,98.2,98.16273,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3919212,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,80.0,80,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3927427,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3929033,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3934857,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,97.3,97.31002,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3942709,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3943932,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,75.0,75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3945382,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,84.2,84.21053,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3951551,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,97.5,97.48954,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3955941,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,61.3,61.29032,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3961070,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,95.3,95.3462,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3966288,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,94.0,94.01775,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3973108,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,37.0,36.97368,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3991838,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3995841,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,1.1,1.11344,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4004886,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,30.0,30,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4007016,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4014063,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,94.6,94.61883,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4016024,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,48.6,48.64753,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4017374,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4019327,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4020835,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,92.5,92.49485,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4030245,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4031312,TB_rdst_num_prct,COUNTRY,BMU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bermuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4031344,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4032862,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,89.4,89.4198,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4040584,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,56.5,56.47059,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4050181,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,51.7,51.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4050263,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4053221,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,11.2,11.22899,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4054472,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.7,86.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4058704,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,76.1,76.10313,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4080837,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,51.5,51.51515,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4088428,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,8.7,8.69565,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4091827,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,90.9,90.90909,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4116279,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,103.7,103.68609,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4135020,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,2.5,2.49089,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4160399,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,63.5,63.54167,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4168821,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,63.6,63.5514,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4179790,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,88.2,88.15789,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4185569,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,36.7,36.70766,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4185806,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,80.6,80.55556,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4188283,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4191774,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,104.3,104.3206,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4194132,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.4,0.39526,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4202175,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,84.5,84.53066,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4203332,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4205243,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,89.9,89.89318,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4212581,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,92.5,92.52616,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4214196,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,94.1,94.07895,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4228357,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4238575,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4243845,TB_rdst_num_prct,COUNTRY,DMA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,14.3,14.28571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Dominica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4246795,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,39.5,39.52959,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4248519,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,97.8,97.75865,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4254328,TB_rdst_num_prct,COUNTRY,MLT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,92.0,92,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malta,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4264192,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,93.5,93.53234,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4265815,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,44.7,44.71545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4267727,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.9,87.9402,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4270313,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4279257,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,94.2,94.17514,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4280044,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.6,78.57662,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4281758,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4289131,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.1,96.14759,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4304544,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4309222,TB_rdst_num_prct,COUNTRY,BRB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Barbados,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4309439,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,115.5,115.5345,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4324786,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4330129,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,14.4,14.36464,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4338086,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,52.7,52.70108,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4340067,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.7,90.66274,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4354691,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,88.9,88.88889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4355033,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4357580,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,93.3,93.28358,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4368599,TB_rdst_num_prct,COUNTRY,PSE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,"occupied Palestinian territory, including east Jerusalem",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4372994,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,15.7,15.74803,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4381846,TB_rdst_num_prct,COUNTRY,COM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Comoros,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4382839,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,53.1,53.08589,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4403147,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,89.1,89.06681,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4405515,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.3,84.26937,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4406393,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,50.6,50.64935,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4426233,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4431195,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,3.6,3.62693,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4434267,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4437456,TB_rdst_num_prct,COUNTRY,KHM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,69.3,69.29577,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cambodia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4441175,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4442657,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4449816,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4454371,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4485550,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4492206,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,99.4,99.3817,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4504457,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,7.5,7.45374,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4509077,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,92.7,92.70362,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4511229,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4517293,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,51.7,51.67464,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4529914,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,79.8,79.80751,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4533047,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4535635,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4547428,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,90.6,90.60366,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4548822,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,98.3,98.30508,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4555830,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.8,0.81805,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4566112,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,73.1,73.13559,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4577163,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4581287,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4588407,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.7,0.67431,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4589669,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4590616,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,30.7,30.67485,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4596614,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,86.4,86.43059,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4600731,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,34.2,34.15094,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4603480,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,20.8,20.78431,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4604269,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,99.1,99.12536,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4606809,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4608113,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,99.7,99.71044,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4612185,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,60.6,60.64155,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4614354,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4615556,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,99.4,99.39302,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4632752,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4639837,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4642912,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4644988,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,75.6,75.60484,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4646535,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,81.2,81.17284,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4658774,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,1.8,1.82407,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4660478,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,84.7,84.72674,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4661589,TB_rdst_num_prct,COUNTRY,AND,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Andorra,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4662046,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,15.2,15.21739,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4665244,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4665821,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4667636,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,70.6,70.56848,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4692296,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,9.0,9.00639,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4708208,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.3,0.34822,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4709372,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,88.2,88.19876,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4715117,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4716678,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4723198,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.4,91.44099,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4724840,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,22.3,22.30833,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4727674,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,96.7,96.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4727753,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,76.6,76.61789,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4728080,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4728484,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.5,0.50548,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4728791,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,15.7,15.70752,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4729984,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,12.2,12.18505,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4742518,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4756879,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4759653,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,93.9,93.88679,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4767148,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,63.8,63.82509,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4773940,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4776088,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,79.5,79.48718,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4790264,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4790405,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4791683,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4795073,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,92.1,92.10526,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4798519,TB_rdst_num_prct,COUNTRY,LBY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,42.4,42.40102,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Libya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4798927,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,38.5,38.46154,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4818067,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4820687,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,88.7,88.68613,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4827409,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,93.7,93.73419,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4829283,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,82.1,82.11207,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4842773,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.8,89.80051,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4842897,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.1,96.10273,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4844499,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4845152,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4863884,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,92.9,92.918450000000007,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4864998,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,6.1,6.1194,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4881659,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,60.0,60,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4883694,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4884663,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4888439,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,99.5,99.49749,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4893399,TB_rdst_num_prct,COUNTRY,BMU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bermuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4894647,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,46.7,46.71533,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4898151,TB_rdst_num_prct,COUNTRY,TKM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Turkmenistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4907626,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,72.6,72.63427,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4907894,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4909253,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.9,92.85714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4909976,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,32.3,32.25806,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4911901,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,90.2,90.19608,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4920226,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4920829,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,12.4,12.36233,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4929601,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.6,89.60223,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4935829,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,67.1,67.08861,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4945200,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,75.7,75.74371,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4945609,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4961416,TB_rdst_num_prct,COUNTRY,KNA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saint Kitts and Nevis,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4972297,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,82.8,82.78388,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4976527,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,21.9,21.87096,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4987444,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,57.1,57.14286,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4991373,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,84.6,84.61538,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4997733,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,82.6,82.63027,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5010937,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,99.6,99.56922,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5012773,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,28.1,28.05459,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5017222,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,97.7,97.70115,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5018249,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,52.1,52.14106,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5032123,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5032787,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,35.4,35.38462,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5037426,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,48.8,48.8,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5046327,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,59.2,59.19164,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5049666,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5063968,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5067450,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5084391,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,2.8,2.82841,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5084577,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,88.1,88.09524,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5089772,TB_rdst_num_prct,COUNTRY,TON,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tonga,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5090165,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,35.3,35.30054,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5090530,TB_rdst_num_prct,COUNTRY,ISL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iceland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5094195,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,2.9,2.89273,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5095028,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5098142,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5098769,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,50.4,50.43534,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5106569,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5106902,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5110667,TB_rdst_num_prct,COUNTRY,SXM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sint Maarten (Dutch part),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5117317,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,85.4,85.35257,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5120447,TB_rdst_num_prct,COUNTRY,LBY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,67.2,67.24782,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Libya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5133808,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,98.7,98.68545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5143338,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,71.4,71.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5144513,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5146474,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5160785,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,7.7,7.68212,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5162388,TB_rdst_num_prct,COUNTRY,LUX,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.0,90,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Luxembourg,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5176245,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,34.3,34.33703,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5179190,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,98.4,98.36066,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5180687,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,90.0,89.99719,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5185008,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,57.8,57.75862,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5188389,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,44.7,44.73684,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5190155,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,8.0,8.04598,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5192113,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.7,94.71175,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5200008,TB_rdst_num_prct,COUNTRY,BMU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bermuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5204981,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5212855,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,8.6,8.56882,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5213529,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,90.8,90.78947,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5214702,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,35.0,34.96867,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5214968,TB_rdst_num_prct,COUNTRY,AND,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Andorra,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5215108,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,92.2,92.1875,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5225828,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5234622,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5244474,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,98.7,98.73418,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5247984,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,51.0,50.99338,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5248086,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,48.0,47.97688,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5250313,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,30.7,30.73248,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5250693,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5255242,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5264382,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5279895,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,22.1,22.09738,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5282661,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,92.4,92.35474,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5290742,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5295718,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.1,89.14508,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5308774,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,94.0,94.0146,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5318521,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,47.8,47.76119,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5328801,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5336450,TB_rdst_num_prct,COUNTRY,CYM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cayman Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5337837,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,74.0,74.03101,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5342544,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,95.1,95.06298,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5343253,TB_rdst_num_prct,COUNTRY,NRU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nauru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5351826,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,4.3,4.29058,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5364542,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5375808,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,38.6,38.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5378084,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,61.5,61.53846,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5383322,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,96.8,96.78639,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5387919,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,66.3,66.28571,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5393863,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5395383,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5405342,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,80.0,80,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5411819,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,5.0,5.00454,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5422080,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5427621,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,70.0,70,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5436143,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,71.4,71.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5444550,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5446398,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,38.0,37.97468,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5451445,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,64.2,64.1768,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5460229,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,95.7,95.68144,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5462660,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,95.3,95.34884,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5465441,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,32.5,32.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5468295,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,75.5,75.4717,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5469330,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.8,86.75035,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5473918,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,84.6,84.61538,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5474509,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5480830,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,47.6,47.61905,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5484968,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,87.8,87.78802,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5495725,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5496631,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,2.8,2.83127,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5498903,TB_rdst_num_prct,COUNTRY,LVA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,93.3,93.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Latvia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5502913,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,74.8,74.76636,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5524111,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.6,90.625,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5531271,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,54.4,54.38395,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5533092,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,10.9,10.89109,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5534124,TB_rdst_num_prct,COUNTRY,COM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Comoros,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5537401,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.9,91.92817,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5537675,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,90.0,89.95327,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5541239,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,50.7,50.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5545565,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,30.5,30.45467,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5556978,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,99.7,99.66791,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5559153,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,69.2,69.23077,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5570969,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,40.4,40.42553,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5571831,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,33.1,33.119,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5577651,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,72.2,72.15569,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5580986,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5582870,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,45.5,45.51724,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5583826,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5587358,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5588059,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5594168,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,65.9,65.94595,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5596534,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,96.6,96.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5597591,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,98.3,98.26319,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5599898,TB_rdst_num_prct,COUNTRY,ASM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,American Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5606656,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5612275,TB_rdst_num_prct,COUNTRY,SLE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,29.5,29.45511,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sierra Leone,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5614679,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,86.3,86.26943,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5620392,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,64.4,64.40678,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5635962,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.6,96.64804,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5638758,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5639968,TB_rdst_num_prct,COUNTRY,PLW,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Palau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5648106,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,101.9,101.89394,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5660743,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,41.7,41.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5667781,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5677279,TB_rdst_num_prct,COUNTRY,KNA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Saint Kitts and Nevis,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5679019,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5681466,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,87.4,87.40125,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5689714,TB_rdst_num_prct,COUNTRY,PSE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,"occupied Palestinian territory, including east Jerusalem",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5705392,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,94.6,94.64717,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5708659,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,66.0,66.02564,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5711742,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,115.9,115.87591,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5716060,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,51.4,51.35135,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5716061,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5719459,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.6,94.60674,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5719840,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,55.5,55.54723,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5726397,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,66.7,66.73554,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5732721,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,97.7,97.65258,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5736337,TB_rdst_num_prct,COUNTRY,LVA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,95.2,95.16129,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Latvia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5739753,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5741033,TB_rdst_num_prct,COUNTRY,LCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,81.8,81.81818,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Saint Lucia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5743245,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,28.6,28.59228,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5752321,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,82.5,82.53968,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5757442,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5757527,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5760187,TB_rdst_num_prct,COUNTRY,AND,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Andorra,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5776919,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,72.6,72.59984,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5777414,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,3.6,3.59116,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5780527,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,88.7,88.72544,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5782899,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,60.1,60.10545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5792226,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,71.2,71.17552,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5801265,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5802462,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,88.1,88.13131,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5806776,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,45.5,45.51445,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5811909,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,79.2,79.22849,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5838588,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,87.5,87.4552,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5841322,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,57.9,57.87966,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5859405,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,66.3,66.25,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5861720,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,53.1,53.07739,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5868316,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5868332,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5869900,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,57.5,57.50799,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5873052,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,25.0,25,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5887376,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5893824,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,86.7,86.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5894589,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5897335,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,47.4,47.36842,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5905412,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5908531,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,6.6,6.61765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5910667,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,78.8,78.78173,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5912451,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5915355,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5927090,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,49.4,49.44444,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5941947,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,71.6,71.57925,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5942805,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,77.6,77.58449,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5943902,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5952396,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5952438,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,115.6,115.6276,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5965091,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.5,97.48428,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5967384,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,10.3,10.29919,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5977051,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,70.6,70.58824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5985726,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.9,84.88,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5995479,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.3,0.2551,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6001074,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,91.1,91.1318,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6002349,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6006281,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,21.4,21.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6010342,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.0,92.9878,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6013856,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,9.7,9.71256,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6016476,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,45.1,45.08197,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6030034,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6040851,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.7,96.72131,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6051614,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6056504,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6063103,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,95.8,95.75114,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6066634,TB_rdst_num_prct,COUNTRY,WSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6069629,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,180.1,180.13572,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6084015,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,93.5,93.52074,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6088122,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,95.8,95.76138,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6090021,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6093193,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,31.1,31.13088,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6095411,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,5.8,5.76271,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6110991,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0.0332,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6119089,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,59.4,59.375,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6125830,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,23.2,23.18841,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6127191,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,63.2,63.21586,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6147973,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,82.8,82.77512,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6150412,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,98.2,98.24561,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6150869,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,24.4,24.42922,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6158459,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,134.7,134.65909,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6165753,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,88.8,88.76404,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6168222,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,94.6,94.62974,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6173788,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,96.2,96.15385,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6176058,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,98.6,98.59155,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6186661,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,99.9,99.88297,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6193220,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6200136,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,59.1,59.14754,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6200150,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6200292,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,85.2,85.15284,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6206726,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,17.4,17.39429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6219100,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,24.9,24.93691,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6238117,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,98.2,98.23804,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6243983,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,92.3,92.32955,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6246144,TB_rdst_num_prct,COUNTRY,WSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6246612,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,81.2,81.20352,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6253352,TB_rdst_num_prct,COUNTRY,ASM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,American Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6260825,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,90.2,90.16832,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6268623,TB_rdst_num_prct,COUNTRY,ERI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Eritrea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6269197,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,39.7,39.66346,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6269665,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,58.6,58.64811,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6278704,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,94.3,94.31818,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6282955,TB_rdst_num_prct,COUNTRY,KWT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kuwait,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6292247,TB_rdst_num_prct,COUNTRY,WSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6298784,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,55.1,55.08197,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6303547,TB_rdst_num_prct,COUNTRY,VCT,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6303550,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6309361,TB_rdst_num_prct,COUNTRY,ESP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,61.0,60.98742,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Spain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6312978,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,15.1,15.08501,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6317992,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6319390,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.2,0.2322,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6319875,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,124.2,124.19257,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6330431,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,90.7,90.73276,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6336342,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6343423,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,67.3,67.29758,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6345843,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,94.1,94.11765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6352612,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,90.7,90.72134,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6353731,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,66.2,66.18257,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6367516,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,93.8,93.80805,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6371276,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,87.8,87.78987,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6384728,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6385826,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,91.3,91.30435,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6389528,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,21.8,21.75052,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6395186,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.5,97.52842,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6408819,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6412096,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,19.3,19.26606,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6431223,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6437937,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.0,92.99497,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6439293,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,32.6,32.60536,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6439558,TB_rdst_num_prct,COUNTRY,MMR,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,86.7,86.72566,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Myanmar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6441290,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,76.9,76.91086,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6450200,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.1,0.07622,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6453607,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,125.0,125,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6457452,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,20.1,20.05484,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6463567,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.8,94.76495,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6466363,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,55.7,55.67505,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6468417,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,88.0,87.95097,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6469461,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.9,94.87179,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6471563,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6494322,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,69.9,69.94364,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6496278,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,27.7,27.69197,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6505444,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,71.0,70.96774,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6511869,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,67.6,67.63285,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6532678,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.6,86.61578,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6534731,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,81.2,81.20903,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6556126,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,99.9,99.91773,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6558090,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,137.3,137.28814,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6564015,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,33.3,33.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6573231,TB_rdst_num_prct,COUNTRY,LBY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,99.1,99.05277,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Libya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6575967,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,64.9,64.85588,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6587446,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,63.9,63.88979,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6587991,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6600569,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,70.7,70.69767,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6603651,TB_rdst_num_prct,COUNTRY,LCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,42.9,42.85714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Saint Lucia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6605928,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,53.4,53.44626,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6612911,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,10.6,10.6309,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6617500,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,86.3,86.3495,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6625885,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.6,87.55714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6632106,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6636978,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,15.6,15.61096,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6637483,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.2,96.21212,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6652046,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6659549,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,193.2,193.24026,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6666669,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,47.8,47.84219,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6670273,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6676815,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6677700,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,80.3,80.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6681187,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,5.2,5.23792,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6682812,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,61.8,61.83369,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6706780,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,25.3,25.29549,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6710547,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,74.2,74.19652,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6717239,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,80.0,80,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6738161,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,98.4,98.37765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6738546,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6748123,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6748933,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,1.9,1.87617,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6752820,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,51.6,51.61343,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6756682,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,70.1,70.14925,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6760601,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6761738,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.2,90.24609,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6763986,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,65.9,65.92809,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6782385,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,45.8,45.84718,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6783084,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6783501,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,96.1,96.05263,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6783559,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,34.8,34.83146,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6786594,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,43.6,43.61974,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6788699,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,14.7,14.68254,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6792338,TB_rdst_num_prct,COUNTRY,KWT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kuwait,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6792943,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,26.1,26.08696,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6793395,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,63.9,63.93273,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6802254,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,94.4,94.4081,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6806354,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.5,91.54663,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6823107,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6830481,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,99.5,99.52381,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6847506,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,84.5,84.46602,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6850367,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,14.1,14.05819,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6850512,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6853601,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,40.0,40,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6857065,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,31.2,31.17342,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6860227,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,25.8,25.77369,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6863612,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,84.8,84.77801,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6866707,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,32.4,32.37154,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6877358,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,95.7,95.65217,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6879747,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,99.6,99.64664,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6889027,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.2,0.1707,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6890108,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6892223,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,41.5,41.49822,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6904145,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6905329,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,29.8,29.75207,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6915050,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,75.0,75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6918234,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.3,87.30159,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6935816,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,88.5,88.46154,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6945107,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,43.6,43.55717,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6946833,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.5,90.47619,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6956762,TB_rdst_num_prct,COUNTRY,ECU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ecuador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6956968,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6984793,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,83.9,83.93023,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6999386,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,65.7,65.72308,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7007789,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,93.2,93.17379,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7015163,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,60.0,60,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7019305,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,57.8,57.77126,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7021361,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,109.6,109.62963,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7027588,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7032905,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,39.7,39.70588,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7040762,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,11.3,11.29509,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7050362,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,88.6,88.60215,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7051372,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,87.3,87.29508,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7058328,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7060036,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,12.1,12.05424,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7080522,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,92.0,92,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7083819,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,99.6,99.58487,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7086059,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,78.8,78.7927,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7094264,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,92.9,92.85714,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7097814,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,99.0,99.04762,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7109054,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,88.6,88.6121,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7110177,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,5.6,5.5922,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7126192,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7126290,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,90.0,90,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7130788,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,82.0,82.00683,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7132750,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,20.8,20.7855,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7132811,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7137900,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,36.0,36.04536,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7159048,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,96.8,96.79487,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7159054,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,80.8,80.78829,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7159120,TB_rdst_num_prct,COUNTRY,LCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,16.7,16.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saint Lucia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7178169,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,2.1,2.12766,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7178769,TB_rdst_num_prct,COUNTRY,RUS,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,95.1,95.14161,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Russian Federation,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7189376,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,84.6,84.62845,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7191726,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7193540,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,14.8,14.80911,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7204404,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,23.7,23.71521,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7208663,TB_rdst_num_prct,COUNTRY,PRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Puerto Rico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7209729,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7219138,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,60.2,60.19417,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7227313,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,21.3,21.32309,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7231252,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7233277,TB_rdst_num_prct,COUNTRY,NIU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Niue,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7238913,TB_rdst_num_prct,COUNTRY,MLT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,93.1,93.10345,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Malta,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7239672,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7242776,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7249138,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,80.1,80.12133,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7253863,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,44.9,44.93168,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7262631,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,42.0,41.97219,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7266793,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7269207,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,80.5,80.54475,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7270946,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,73.9,73.91304,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7271235,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,88.6,88.61985,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7271611,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,13.7,13.6891,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7271629,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,103.6,103.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7279999,TB_rdst_num_prct,COUNTRY,SLV,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,26.4,26.39311,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,El Salvador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7280683,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,98.6,98.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7285325,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,91.4,91.354,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7290773,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7291512,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7293455,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7293759,TB_rdst_num_prct,COUNTRY,ASM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,American Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7298559,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,77.1,77.06767,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7299013,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,8.5,8.52866,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7307258,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,48.9,48.90342,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7312249,TB_rdst_num_prct,COUNTRY,JPN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,59.7,59.71223,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Japan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7312632,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,97.3,97.33978,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7317256,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,78.5,78.48101,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7324298,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,98.2,98.18182,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7335721,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7336375,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,73.0,73.01444,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7339932,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7340762,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,95.1,95.09346,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7350509,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,84.9,84.90556,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7354299,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,54.1,54.05007,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7355540,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7357363,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7363303,TB_rdst_num_prct,COUNTRY,TON,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tonga,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7368323,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7374111,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,92.3,92.29259,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7380097,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7390792,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,86.3,86.34216,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7393215,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,76.6,76.59574,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7393774,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,89.7,89.66708,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7394777,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7413808,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,3.9,3.87166,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7423875,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,88.5,88.46154,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7429461,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,90.3,90.2521,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7444088,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.6,96.5812,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7455950,TB_rdst_num_prct,COUNTRY,COM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,20.0,20,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Comoros,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7460758,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,90.5,90.53212,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7470156,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7472253,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,97.3,97.30345,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7472519,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,81.5,81.52174,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7472647,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,2.4,2.40082,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7475534,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,9.1,9.05775,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7487720,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,87.3,87.27273,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7512843,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,96.6,96.61134,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7518841,TB_rdst_num_prct,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,88.3,88.2716,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Iraq,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7520749,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,20.4,20.39772,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7524617,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,88.0,88.0022,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7529024,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,76.7,76.69713,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7530405,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,83.3,83.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7531723,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,19.1,19.14894,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7539820,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,60.0,59.95175,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7542644,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,11.2,11.23059,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7566356,TB_rdst_num_prct,COUNTRY,BRB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Barbados,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7568644,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7573201,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,48.1,48.05195,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7581305,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7585192,TB_rdst_num_prct,COUNTRY,MNE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Montenegro,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7592671,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7597869,TB_rdst_num_prct,COUNTRY,TKM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Turkmenistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7600261,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,99.0,98.97436,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7600520,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7612191,TB_rdst_num_prct,COUNTRY,BHS,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bahamas,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7612811,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7612969,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,88.9,88.88889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7618450,TB_rdst_num_prct,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Syrian Arab Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7627116,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,68.5,68.52151,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7646516,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,93.3,93.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7652695,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,38.9,38.90373,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7652812,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,49.7,49.70764,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7665007,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,40.7,40.66053,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7666320,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,69.0,69.01408,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7666448,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7668966,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,85.6,85.61151,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7671729,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,54.5,54.52489,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7692982,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,89.5,89.48655,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7697670,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,84.2,84.21053,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7699070,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7703739,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,8.0,7.98722,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7712901,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7717351,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,87.8,87.81337,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7726051,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,81.2,81.20805,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7745608,TB_rdst_num_prct,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,69.0,69,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saudi Arabia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7747089,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,59.9,59.91751,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7751599,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7757307,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,1.9,1.9443,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7758674,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,74.1,74.07407,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7764016,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.4,93.35664,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7794321,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,3.3,3.30551,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7798400,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7800984,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,31.5,31.52174,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7813372,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,45.6,45.58824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7815700,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,83.2,83.19897,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7817489,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,93.3,93.31586,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7817666,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,87.3,87.25212,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7820747,TB_rdst_num_prct,COUNTRY,LBN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,89.9,89.93711,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lebanon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7835389,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7837631,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.8,78.82353,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7843772,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,94.6,94.59459,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7853598,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,78.0,77.96482,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7855336,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,89.5,89.51311,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7857916,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,86.7,86.7031,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7860894,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,72.6,72.55042,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7863142,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,95.2,95.18072,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7866220,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7866597,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7868186,TB_rdst_num_prct,COUNTRY,WSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7872197,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,72.2,72.22222,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7881232,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,98.0,97.97688,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7899102,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7910539,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,200.0,200,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7912618,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7916714,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,62.4,62.44171,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7918665,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,37.2,37.15929,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7919059,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,71.6,71.59483,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7922517,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7924067,TB_rdst_num_prct,COUNTRY,HTI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,11.9,11.93182,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Haiti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7925958,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7928883,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,95.8,95.76301,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7949576,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,87.0,87.01299,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7961705,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,7.0,6.98459,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7975961,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,83.7,83.65659,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7976469,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.2,84.21053,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7977039,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,69.8,69.84402,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7978329,TB_rdst_num_prct,COUNTRY,AND,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,50.0,50,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Andorra,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7979631,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7989013,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,93.5,93.53869,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8000768,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.1,0.11406,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8006689,TB_rdst_num_prct,COUNTRY,BMU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bermuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8007670,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8021867,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,22.2,22.22222,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8027210,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8033854,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8039571,TB_rdst_num_prct,COUNTRY,JAM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Jamaica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8051104,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,42.5,42.4581,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8055489,TB_rdst_num_prct,COUNTRY,MWI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,39.5,39.5202,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Malawi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8057364,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8060144,TB_rdst_num_prct,COUNTRY,TTO,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,70.6,70.58824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Trinidad and Tobago,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8065457,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,73.7,73.68421,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8081114,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,47.2,47.16459,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8085622,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,61.7,61.70213,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8091995,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.4,0.37709,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8094589,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.7,0.69785,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8095090,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8097462,TB_rdst_num_prct,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,75.5,75.51182,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Pakistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8104659,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.7,89.65517,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8107177,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8115215,TB_rdst_num_prct,COUNTRY,COM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Comoros,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8121484,TB_rdst_num_prct,COUNTRY,CYP,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Cyprus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8121961,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,91.6,91.6129,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8127475,TB_rdst_num_prct,COUNTRY,NIU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Niue,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8150174,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8152602,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,79.5,79.54545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8157067,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,65.8,65.84735,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8161066,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8163408,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8164291,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,86.9,86.86076,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8169768,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,88.8,88.84832,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8172037,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,13.2,13.19149,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8173156,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.3,96.2963,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8175899,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,126.5,126.46607,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8190591,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8201617,TB_rdst_num_prct,COUNTRY,SWZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Eswatini,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8203313,TB_rdst_num_prct,COUNTRY,BDI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,31.1,31.10024,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Burundi,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8212356,TB_rdst_num_prct,COUNTRY,FSM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,85.7,85.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Micronesia (Federated States of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8215068,TB_rdst_num_prct,COUNTRY,TON,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tonga,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8219204,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,91.8,91.78082,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8238610,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8253629,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,61.3,61.33751,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8255678,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,99.8,99.81238,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8258319,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8269730,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,71.4,71.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8298356,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,93.5,93.47826,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8300271,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,94.6,94.62518,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8301031,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,61.1,61.11111,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8303430,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8304691,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,63.4,63.40637,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8308466,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8312384,TB_rdst_num_prct,COUNTRY,STP,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,50.0,50,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sao Tome and Principe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8324250,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,91.9,91.93548,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8326119,TB_rdst_num_prct,COUNTRY,CMR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,47.8,47.80832,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cameroon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8329189,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,20.4,20.37072,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8336619,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,53.0,52.97054,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8339385,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8345952,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,98.9,98.93617,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8350360,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,12.5,12.5,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8369224,TB_rdst_num_prct,COUNTRY,TGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Togo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8369344,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,65.3,65.33364,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8374720,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8379428,TB_rdst_num_prct,COUNTRY,LTU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lithuania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8384794,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8386196,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,36.8,36.84211,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8397243,TB_rdst_num_prct,COUNTRY,EST,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,99.2,99.19355,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Estonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8399050,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,118.5,118.51475,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8402010,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,92.4,92.38121,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8408101,TB_rdst_num_prct,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,69.7,69.69697,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Arab Emirates,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8408780,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,59.2,59.24444,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8417145,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8420849,TB_rdst_num_prct,COUNTRY,IDN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,94.3,94.30055,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Indonesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8436188,TB_rdst_num_prct,COUNTRY,ECU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,110.6,110.64792,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ecuador,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8438014,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,46.7,46.71107,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8438357,TB_rdst_num_prct,COUNTRY,MLT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,82.2,82.22222,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Malta,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8439438,TB_rdst_num_prct,COUNTRY,LCA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Saint Lucia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8441265,TB_rdst_num_prct,COUNTRY,MNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mongolia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8444242,TB_rdst_num_prct,COUNTRY,DJI,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Djibouti,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8450186,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,79.5,79.45205,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8454687,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,62.3,62.33401,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8470780,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,59.4,59.42067,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8496941,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,75.7,75.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8503884,TB_rdst_num_prct,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,89.0,89.0024,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Egypt,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8504273,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8507784,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,55.8,55.7971,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8509005,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8516266,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,94.6,94.64668,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8517995,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8525883,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,32.7,32.65742,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8527181,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8528903,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,85.4,85.42403,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8529142,TB_rdst_num_prct,COUNTRY,DMA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Dominica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8538379,TB_rdst_num_prct,COUNTRY,LUX,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,95.5,95.45455,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Luxembourg,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8541182,TB_rdst_num_prct,COUNTRY,ATG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Antigua and Barbuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8552527,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,43.5,43.53994,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8560024,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,23.1,23.08892,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8576712,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,3.5,3.53021,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8580716,TB_rdst_num_prct,COUNTRY,POL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,89.5,89.50635,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Poland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8596860,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,57.9,57.89474,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8597547,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,67.3,67.34463,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8630792,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8635244,TB_rdst_num_prct,COUNTRY,NAM,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,86.8,86.78116,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Namibia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8653096,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,71.1,71.12971,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8654077,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,49.0,48.97242,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8655478,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,20.5,20.52709,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8662593,TB_rdst_num_prct,COUNTRY,DEU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,87.6,87.60611,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Germany,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8676823,TB_rdst_num_prct,COUNTRY,KWT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kuwait,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8686649,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,96.2,96.24921,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8692702,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,53.1,53.125,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8702313,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8707342,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,88.6,88.63636,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8714578,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,89.7,89.70874,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8732917,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,36.8,36.80154,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8735500,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,63.1,63.12953,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8739880,TB_rdst_num_prct,COUNTRY,KWT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Kuwait,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8742191,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,59.9,59.89848,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8745269,TB_rdst_num_prct,COUNTRY,TUV,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Tuvalu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8749295,TB_rdst_num_prct,COUNTRY,WLF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Wallis and Futuna Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8751070,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,71.0,71.01449,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8753963,TB_rdst_num_prct,COUNTRY,TUR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,87.7,87.71003,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Trkiye,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8757126,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,76.1,76.1194,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8758554,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,73.5,73.45143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8782120,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,93.4,93.361,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8787105,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8788681,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8797852,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,15.3,15.31664,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8812850,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,41.9,41.88123,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8829998,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,54.5,54.54545,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8838451,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,63.9,63.8806,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8846093,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,71.4,71.44859,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8851226,TB_rdst_num_prct,COUNTRY,ROU,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,89.2,89.2289,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Romania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8860436,TB_rdst_num_prct,COUNTRY,ETH,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,35.5,35.54882,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ethiopia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8860844,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,54.5,54.48165,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8869422,TB_rdst_num_prct,COUNTRY,CIV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,99.9,99.90449,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cote d'Ivoire,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8870971,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8878251,TB_rdst_num_prct,COUNTRY,NCL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,New Caledonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8881901,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,63.9,63.92634,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8882209,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,50.1,50.05482,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8884971,TB_rdst_num_prct,COUNTRY,CPV,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,81.8,81.81818,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Cabo Verde,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8890293,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,86.3,86.27002,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8906444,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,22.6,22.56815,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8915600,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,91.8,91.80691,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8930054,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.0,92.96146,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8935118,TB_rdst_num_prct,COUNTRY,HKG,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,95.9,95.90667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"China, Hong Kong Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8935444,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8962191,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,76.0,76.00062,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8966757,TB_rdst_num_prct,COUNTRY,ZAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,91.9,91.85479,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,South Africa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8976479,TB_rdst_num_prct,COUNTRY,ISL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iceland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8977198,TB_rdst_num_prct,COUNTRY,PNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Papua New Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8994201,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9005492,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,105.6,105.6338,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9011165,TB_rdst_num_prct,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,25.0,25,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Jordan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9035826,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9037988,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,88.9,88.87117,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9038196,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,84.7,84.65267,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9040355,TB_rdst_num_prct,COUNTRY,THA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,76.1,76.10879,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Thailand,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9052485,TB_rdst_num_prct,COUNTRY,ARG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,24.8,24.8227,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Argentina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9055742,TB_rdst_num_prct,COUNTRY,BMU,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bermuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9057374,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,97.1,97.10145,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9072209,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.3,91.29383,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9092959,TB_rdst_num_prct,COUNTRY,TCD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,8.6,8.62215,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Chad,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9116830,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9124465,TB_rdst_num_prct,COUNTRY,CRI,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,41.9,41.9244,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Costa Rica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9139613,TB_rdst_num_prct,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,51.4,51.38249,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Qatar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9140768,TB_rdst_num_prct,COUNTRY,TZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,64.9,64.92698,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Republic of Tanzania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9142090,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,68.3,68.29268,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9143479,TB_rdst_num_prct,COUNTRY,BWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,29.0,28.98833,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Botswana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9144019,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,94.1,94.11765,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9166255,TB_rdst_num_prct,COUNTRY,CUB,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,82.7,82.71605,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cuba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9174921,TB_rdst_num_prct,COUNTRY,USA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,89.4,89.41927,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United States of America,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9198541,TB_rdst_num_prct,COUNTRY,VUT,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Vanuatu,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9202838,TB_rdst_num_prct,COUNTRY,LKA,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,96.4,96.41944,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sri Lanka,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9226822,TB_rdst_num_prct,COUNTRY,SVN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9228116,TB_rdst_num_prct,COUNTRY,GIN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,1.9,1.90078,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9230649,TB_rdst_num_prct,COUNTRY,DMA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Dominica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9235417,TB_rdst_num_prct,COUNTRY,FRA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,4.8,4.7619,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,France,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9236851,TB_rdst_num_prct,COUNTRY,BFA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,75.1,75.06361,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Burkina Faso,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9247946,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9254857,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,51.4,51.37085,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9256474,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,50.5,50.46756,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9277786,TB_rdst_num_prct,COUNTRY,LUX,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,76.2,76.19048,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Luxembourg,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9295283,TB_rdst_num_prct,COUNTRY,FIN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,91.4,91.36691,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Finland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9300597,TB_rdst_num_prct,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,93.8,93.75,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tunisia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9301655,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,26.9,26.88442,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9304924,TB_rdst_num_prct,COUNTRY,MUS,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mauritius,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9311452,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,19.7,19.66001,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9312133,TB_rdst_num_prct,COUNTRY,NRU,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nauru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9317659,TB_rdst_num_prct,COUNTRY,GRC,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,54.6,54.64286,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Greece,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9321410,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.0,86.01399,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9343878,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,85.8,85.7971,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9350074,TB_rdst_num_prct,COUNTRY,SXM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sint Maarten (Dutch part),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9374276,TB_rdst_num_prct,COUNTRY,COD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,22.3,22.30122,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Democratic Republic of the Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9394545,TB_rdst_num_prct,COUNTRY,BGD,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bangladesh,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9396262,TB_rdst_num_prct,COUNTRY,MOZ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,99.8,99.79644,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mozambique,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9404643,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,67.6,67.56757,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9410066,TB_rdst_num_prct,COUNTRY,YEM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,19.4,19.4011,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Yemen,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9421038,TB_rdst_num_prct,COUNTRY,KWT,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kuwait,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9422705,TB_rdst_num_prct,COUNTRY,NGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,91.1,91.09415,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nigeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9426550,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9427157,TB_rdst_num_prct,COUNTRY,SSD,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,4.6,4.61043,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,South Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9440823,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,42.3,42.28245,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9442845,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0.02549,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9456396,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,21.8,21.76208,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9467653,TB_rdst_num_prct,COUNTRY,ARM,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,98.2,98.15951,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Armenia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9469690,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,2.3,2.30786,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9480064,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,80.9,80.87318,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9480710,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,56.9,56.85904,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9486163,TB_rdst_num_prct,COUNTRY,HND,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,43.7,43.74337,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Honduras,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9492772,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,89.6,89.57055,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9500402,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,49.4,49.44219,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9501654,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,94.0,94.04006,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9515318,TB_rdst_num_prct,COUNTRY,PYF,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,French Polynesia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9515796,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,94.3,94.28036,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9517476,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,83.5,83.4965,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9518031,TB_rdst_num_prct,COUNTRY,GTM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guatemala,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9518042,TB_rdst_num_prct,COUNTRY,BLZ,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,28.6,28.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belize,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9522720,TB_rdst_num_prct,COUNTRY,DZA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,30.3,30.31359,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Algeria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9530148,TB_rdst_num_prct,COUNTRY,SLE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,37.8,37.76467,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sierra Leone,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9533981,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,73.4,73.37662,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9547487,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9552231,TB_rdst_num_prct,COUNTRY,ASM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,American Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9552391,TB_rdst_num_prct,COUNTRY,VNM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,98.4,98.37464,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Viet Nam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9554143,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,61.0,61.00478,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9563624,TB_rdst_num_prct,COUNTRY,DMA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Dominica,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9565217,TB_rdst_num_prct,COUNTRY,DNK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,97.7,97.71429,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Denmark,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9565825,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,1.3,1.28234,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9567386,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,97.3,97.2973,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9571368,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.9,0.87822,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9577197,TB_rdst_num_prct,COUNTRY,MDV,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,59.0,59.04762,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Maldives,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9580932,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.2,78.21901,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9581918,TB_rdst_num_prct,COUNTRY,IND,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,88.7,88.65288,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,India,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9583596,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,17.1,17.12826,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9587994,TB_rdst_num_prct,COUNTRY,UZB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Uzbekistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9589460,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,86.0,86.02151,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9591423,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9596802,TB_rdst_num_prct,COUNTRY,NOR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,96.2,96.15385,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Norway,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9597711,TB_rdst_num_prct,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bahrain,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9600228,TB_rdst_num_prct,COUNTRY,BOL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,74.2,74.20328,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bolivia (Plurinational State of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9603503,TB_rdst_num_prct,COUNTRY,AUS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,94.1,94.11012,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Australia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9615641,TB_rdst_num_prct,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,84.6,84.64017,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Somalia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9621921,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.3,91.31719,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9632671,TB_rdst_num_prct,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,79.9,79.90968,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Sudan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9635573,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9644186,TB_rdst_num_prct,COUNTRY,MDG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Madagascar,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9655643,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,86.1,86.05474,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9659143,TB_rdst_num_prct,COUNTRY,AZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,98.9,98.86264,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Azerbaijan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9688926,TB_rdst_num_prct,COUNTRY,CAF,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,9.7,9.74889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Central African Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9690497,TB_rdst_num_prct,COUNTRY,NLD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,53.8,53.84615,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Netherlands (Kingdom of the),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9694288,TB_rdst_num_prct,COUNTRY,BEL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,89.7,89.70588,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belgium,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9695804,TB_rdst_num_prct,COUNTRY,GRD,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Grenada,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9735758,TB_rdst_num_prct,COUNTRY,GBR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,77.2,77.22772,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9737994,TB_rdst_num_prct,COUNTRY,GHA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,93.5,93.49224,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ghana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9766397,TB_rdst_num_prct,COUNTRY,CHN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,79.9,79.9055,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,China,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9770433,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,35.8,35.75949,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9774775,TB_rdst_num_prct,COUNTRY,ATG,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Antigua and Barbuda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9779458,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,7.3,7.33333,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9792830,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9802775,TB_rdst_num_prct,COUNTRY,NER,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,1.8,1.77113,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Niger,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9805880,TB_rdst_num_prct,COUNTRY,BTN,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Bhutan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9817267,TB_rdst_num_prct,COUNTRY,MEX,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,54.4,54.36537,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mexico,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9827852,TB_rdst_num_prct,COUNTRY,KGZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,93.9,93.94347,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kyrgyzstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9837486,TB_rdst_num_prct,COUNTRY,HUN,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,85.2,85.2459,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Hungary,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9855158,TB_rdst_num_prct,COUNTRY,KAZ,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,99.7,99.72997,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kazakhstan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9863394,TB_rdst_num_prct,COUNTRY,AUT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,86.9,86.93467,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Austria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9865630,TB_rdst_num_prct,COUNTRY,PER,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,77.6,77.56399,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Peru,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9882363,TB_rdst_num_prct,COUNTRY,PNG,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Papua New Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9885300,TB_rdst_num_prct,COUNTRY,ASM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,American Samoa,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9888724,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9898094,TB_rdst_num_prct,COUNTRY,MNP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Northern Mariana Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9899523,TB_rdst_num_prct,COUNTRY,GAB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,32.6,32.55345,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Gabon,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9901164,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,27.5,27.48344,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9918524,TB_rdst_num_prct,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,78.5,78.49687,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iran (Islamic Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9920370,TB_rdst_num_prct,COUNTRY,ABW,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Aruba,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9928097,TB_rdst_num_prct,COUNTRY,TLS,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,16.3,16.3353,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Timor-Leste,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9943847,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9951833,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9953815,TB_rdst_num_prct,COUNTRY,MLT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Malta,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9964638,TB_rdst_num_prct,COUNTRY,SVK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,81.0,80.95238,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovakia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9966324,TB_rdst_num_prct,COUNTRY,BLR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belarus,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9975079,TB_rdst_num_prct,COUNTRY,LSO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,91.4,91.37931,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Lesotho,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9976303,TB_rdst_num_prct,COUNTRY,FJI,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Fiji,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9984004,TB_rdst_num_prct,COUNTRY,SRB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,63.8,63.82979,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Serbia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9984077,TB_rdst_num_prct,COUNTRY,UGA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,61.4,61.36346,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uganda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9984261,TB_rdst_num_prct,COUNTRY,COL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,39.2,39.175,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Colombia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9989570,TB_rdst_num_prct,COUNTRY,BRA,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,59.1,59.05382,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Brazil,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9997508,TB_rdst_num_prct,COUNTRY,SYC,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Seychelles,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9998821,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,15.4,15.35443,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9999607,TB_rdst_num_prct,COUNTRY,PRK,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,3.6,3.62903,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Democratic People's Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10000788,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10003868,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,88.9,88.88889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10004162,TB_rdst_num_prct,COUNTRY,ISR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Israel,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10006805,TB_rdst_num_prct,COUNTRY,HRV,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,78.6,78.57143,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Croatia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10009239,TB_rdst_num_prct,COUNTRY,NPL,YEAR,SEAR,South-East Asia,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,81.3,81.26456,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nepal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10011635,TB_rdst_num_prct,COUNTRY,SEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Senegal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10014503,TB_rdst_num_prct,COUNTRY,DOM,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,88.3,88.34951,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Dominican Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10020246,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10021019,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10024953,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,59.3,59.30824,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10030502,TB_rdst_num_prct,COUNTRY,CHE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,90.8,90.81633,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Switzerland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10051403,TB_rdst_num_prct,COUNTRY,IRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,80.0,80,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Ireland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10053707,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,97.7,97.67442,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10058056,TB_rdst_num_prct,COUNTRY,URY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.4,84.375,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uruguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10063037,TB_rdst_num_prct,COUNTRY,PHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,84.9,84.91878,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Philippines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10066486,TB_rdst_num_prct,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,7.2,7.24221,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Morocco,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10082331,TB_rdst_num_prct,COUNTRY,MHL,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,0.0,0,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Marshall Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10091615,TB_rdst_num_prct,COUNTRY,ZWE,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,97.0,96.97802,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Zimbabwe,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10094065,TB_rdst_num_prct,COUNTRY,TJK,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Tajikistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10100331,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,91.7,91.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10120545,TB_rdst_num_prct,COUNTRY,AGO,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,9.0,9.01404,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Angola,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10138166,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10138520,TB_rdst_num_prct,COUNTRY,KIR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.1,91.09948,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kiribati,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10143172,TB_rdst_num_prct,COUNTRY,MLI,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,8.4,8.44749,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Mali,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10147792,TB_rdst_num_prct,COUNTRY,VEN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,25.6,25.62358,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10148849,TB_rdst_num_prct,COUNTRY,MRT,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,92.2,92.15686,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mauritania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10149131,TB_rdst_num_prct,COUNTRY,ISL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Iceland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10171678,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.9,0.86163,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10171711,TB_rdst_num_prct,COUNTRY,GNQ,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,89.3,89.32039,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Equatorial Guinea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10174054,TB_rdst_num_prct,COUNTRY,COG,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Congo,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10192065,TB_rdst_num_prct,COUNTRY,UKR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,96.9,96.87859,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Ukraine,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10193231,TB_rdst_num_prct,COUNTRY,LBR,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,18.3,18.34862,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Liberia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10199026,TB_rdst_num_prct,COUNTRY,SWE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,84.6,84.61538,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sweden,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10200040,TB_rdst_num_prct,COUNTRY,MYS,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,76.2,76.18026,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malaysia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10209767,TB_rdst_num_prct,COUNTRY,PAN,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,49.4,49.4382,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Panama,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10210488,TB_rdst_num_prct,COUNTRY,KOR,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,87.7,87.74536,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Republic of Korea,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10214780,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,60.0,60,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
10227977,TB_rdst_num_prct,COUNTRY,MKD,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,North Macedonia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
317518,TB_rdst_num_prct,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,91.6,91.59664,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Oman,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
425059,TB_rdst_num_prct,COUNTRY,BRN,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Brunei Darussalam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
773595,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,96.4,96.40078,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
875235,TB_rdst_num_prct,COUNTRY,GUM,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guam,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
900520,TB_rdst_num_prct,COUNTRY,GRL,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2017,NA,NA,NA,NA,NA,NA,63.9,63.88889,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Greenland,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1304461,TB_rdst_num_prct,COUNTRY,MDA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,80.2,80.15979,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Republic of Moldova,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1475560,TB_rdst_num_prct,COUNTRY,BIH,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,95.6,95.55556,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bosnia and Herzegovina,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1722465,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,82.4,82.35294,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1754118,TB_rdst_num_prct,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2021,NA,NA,NA,NA,NA,NA,70.6,70.57657,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Afghanistan,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
1994213,TB_rdst_num_prct,COUNTRY,SGP,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,98.2,98.15838,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Singapore,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2291634,TB_rdst_num_prct,COUNTRY,VCT,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2405779,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,50.2,50.15106,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2431215,TB_rdst_num_prct,COUNTRY,SLB,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Solomon Islands,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2566433,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,71.5,71.51899,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2777690,TB_rdst_num_prct,COUNTRY,SUR,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,98.5,98.50746,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Suriname,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
2871326,TB_rdst_num_prct,COUNTRY,ALB,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Albania,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
3370600,TB_rdst_num_prct,COUNTRY,GUY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,87.8,87.76758,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Guyana,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4089480,TB_rdst_num_prct,COUNTRY,CZE,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,66.7,66.66667,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Czechia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4330659,TB_rdst_num_prct,COUNTRY,GNB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,96.0,96,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guinea-Bissau,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4495440,TB_rdst_num_prct,COUNTRY,GEO,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2018,NA,NA,NA,NA,NA,NA,97.3,97.33136,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Georgia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4628720,TB_rdst_num_prct,COUNTRY,NIC,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2018,NA,NA,NA,NA,NA,NA,54.5,54.49102,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Nicaragua,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
4971163,TB_rdst_num_prct,COUNTRY,ZMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,75.2,75.17695,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Zambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5098058,TB_rdst_num_prct,COUNTRY,ITA,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,97.0,97.04209,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Italy,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5211830,TB_rdst_num_prct,COUNTRY,RWA,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,72.6,72.63302,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Rwanda,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5294283,TB_rdst_num_prct,COUNTRY,KEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,92.1,92.11823,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Kenya,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5820622,TB_rdst_num_prct,COUNTRY,GMB,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2019,NA,NA,NA,NA,NA,NA,0.1,0.06378,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Gambia,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
5865017,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2020,NA,NA,NA,NA,NA,NA,47.5,47.45763,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
6512144,TB_rdst_num_prct,COUNTRY,LAO,YEAR,WPR,Western Pacific,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_NEW,2020,NA,NA,NA,NA,NA,NA,89.0,88.9979,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lao People's Democratic Republic,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
7603971,TB_rdst_num_prct,COUNTRY,PRT,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,46.4,46.42857,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Portugal,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8593498,TB_rdst_num_prct,COUNTRY,CHL,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,90.6,90.57377,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Chile,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8745734,TB_rdst_num_prct,COUNTRY,MAC,YEAR,NA,NA,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2019,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,"China, Macao Special Administrative Region",The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8815412,TB_rdst_num_prct,COUNTRY,PRY,YEAR,AMR,Americas,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Paraguay,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
8821790,TB_rdst_num_prct,COUNTRY,BGR,YEAR,EUR,Europe,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2021,NA,NA,NA,NA,NA,NA,43.9,43.90244,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2021,2021-01-01T00:00:00+01:00,2021-12-31T00:00:00+01:00,Bulgaria,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
9126364,TB_rdst_num_prct,COUNTRY,BEN,YEAR,AFR,Africa,TB_TREATHISTORY,TB_TREATHISTORY_TB_TREATHISTORY_RETREATED,2017,NA,NA,NA,NA,NA,NA,100.0,100,NA,NA,NA,2024-05-06T09:56:42.727+02:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Benin,The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.,EN,TB Treatment history
